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Background: Transforming growth factor-βs (TGF-βs) are a group of multifunctional proteins that have
neuroprotective roles in various experimental models. We previously reported that intrathecal (i.t.) injections of
TGF-β1 significantly inhibit neuropathy-induced thermal hyperalgesia, spinal microglia and astrocyte activation, as
well as upregulation of tumor necrosis factor-α. However, additional cellular mechanisms for the antinociceptive
effects of TGF-β1, such as the mitogen-activated protein kinase (MAPK) pathway, have not been elucidated. During
persistent pain, activation of MAPKs, especially p38 and extracellular signal-regulated kinase (ERK), have crucial roles in
the induction and maintenance of pain hypersensitivity, via both nontranscriptional and transcriptional regulation. In
the present study, we used a chronic constriction injury (CCI) rat model to explore the role of spinal p38 and ERK in the
analgesic effects of TGF-β1.
Methods: We investigated the cellular mechanisms of the antinociceptive effects of i.t. injections of TGF-β1 in CCI
induced neuropathic rats by spinal immunohistofluorescence analyses.
Results: The results demonstrated that the antinociceptive effects of TGF-β1 (5 ng) were maintained at greater than
50 % of the maximum possible effect in rats with CCI for at least 6 h after a single i.t. administration. Thus, we further
examined these alterations in spinal p38 and ERK from 0.5 to 6 h after i.t. administration of TGF-β1. TGF-β1 significantly
attenuated CCI-induced upregulation of phosphorylated p38 (phospho-p38) and phosphorylated ERK (phospho-ERK)
expression in the dorsal horn of the lumbar spinal cord. Double immunofluorescence staining illustrated that
upregulation of spinal phospho-p38 was localized to neurons, activated microglial cells, and activated astrocytes in rats
with CCI. Additionally, increased phospho-ERK occurred in activated microglial cells and activated astrocytes.
Furthermore, i.t. administration of TGF-β1 markedly inhibited phospho-p38 upregulation in neurons, microglial cells,
and astrocytes. However, i.t. injection of TGF-β1 also reduced phospho-ERK upregulation in microglial cells and
astrocytes.
Conclusions: The present results demonstrate that suppressing p38 and ERK activity affects TGF-β1-induced analgesia
during neuropathy.
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Globally, 1.5 billion people experience pain [1]. Chronic
pain occurs in approximately 20 % of the general popu-
lation [2, 3], and the prevalence of neuropathic pain has
been reported at 6.9 % [3]. Furthermore, drug treatments
are not capable of relieving all neuropathic pain condi-
tions [4, 5]. The cellular mechanisms of neuropathic
pain are complex and have not been fully elucidated. In
2009, Echeverry et al. reported that intrathecal (i.t.) infu-
sion of transforming growth factor-β1 (TGF-β1) signifi-
cantly attenuated nerve injury-induced neuropathic pain
in rats [6], which suggests two primary research direc-
tions. First, the antinociceptive properties of TGF-β1 [7]
and its mechanisms [8, 9] must be elucidated. Second,
research is required in order to investigate direct in-
volvement of TGF-β1 in the antinociceptive mechanisms
of drug compounds [10] or cell-based therapies [9].
However, only a few subsequent studies have investi-
gated the cellular mechanisms of the antinociceptive ef-
fects of TGF-β1.
During neuropathy, spinal cord neuroinflammation
may promote central sensitization, thereby contributing
to the development and maintenance of pain [11, 12].
Spinal neuroinflammation in peripheral neuropathy is
characterized by activation of microglia and astrocytes,
as well as upregulation of the proinflammatory mediator,
tumor necrosis factor-α (TNF-α) [8, 13, 14]. Microglia
and astrocytes synthesize TNF-α [15], and TNF-α con-
tributes to neuropathic pain [16, 17]. Additionally, inhi-
biting activation of microglia and astrocytes [18–20], as
well as spinal TNF-α [21] have analgesic effects. Activa-
tion of p38 or extracellular signal-regulated kinase
(ERK), subgroups of mitogen activated protein kinases
(MAPKs), stimulate TNF-α gene expression in primary
microglia and astrocytes [15]. Furthermore, peripheral
nerve injury and spinal cord injury activate spinal p38
and ERK [22–24]. Several previous studies have sug-
gested that inhibiting p38 [22, 23, 25] and ERK [24] ac-
tivity are potential therapeutic strategies for neuropathic
pain. However, information is limited regarding the roles
of p38 and ERK in the antinociceptive effects of TGF-β1
in rat models of neuropathy. In the present study, we ex-
amined the effects of i.t. TGF-β1 on p38 and ERK activa-
tion in the spinal cord of rats with chronic constriction
injury (CCI), a commonly used model of neuropathic
pain [26]. We also assessed alterations in the time
courses for the antinociceptive effects of TGF-β1 and for
activation of p38 and ERK in rats with CCI, in order to
further investigate the roles of p38 and ERK in both the
development and maintenance of the antinociceptive ef-
fects of TGF-β1 during neuropathic pain. We then stud-
ied cellular specificity of the effects on p38 and ERK
activation in neuropathic rats, including in neurons,
microglia, and astrocytes.Methods
Animals
Male Wistar rats (260–285 g) were housed in a
temperature- (22 ± 1 °C) and light-cycle-controlled (12 h
light/12 h dark) experimental animal house, with free ac-
cess to food and water. We complied with the Guiding
Principles in the Care and Use of Animals of the American
Physiology Society and all experiments were approved by
the National Sun Yat-sen University and Use Committee.
Rats were anesthetized by isoflurane inhalation (2 %) for
surgery and drug injections, and all rats received postoper-
ative administration of intramuscular veterin (cefazolin;
0.17 g/kg) in order to prevent infection. The experimental
design and procedures aimed to minimize the number of
rats used and any distress that they would experience.
Induction of peripheral mononeuropathy
CCI surgeries were performed on the right sciatic nerve
of rats, using the method described by Bennett and Xie
[26] and in our previous studies [13, 18]. In brief, we ex-
posed the right sciatic nerve at mid-thigh level, dissected
a 5 mm length of nerve, applied four loose ligatures
around the sciatic nerve (4-0 chromic gut at 1 mm inter-
vals), and then sutured both the muscle and the skin in-
cision. For the sham-operated group, we exposed the
right sciatic nerve but did not perform ligation.
Implantation of i.t. catheters
We implanted i.t. catheters (PE5 tubes: 9 cm long, 0.008
in. inner diameter, 0.014 in. outer diameter; Spectranetics,
Colorado Springs, CO, USA) to the lumbar enlargement
of the spinal cord, via the atlanto-occipital membrane at
the base of the skull, as previously described by Yaksh and
Rudy [27] and our previous studies [13, 18]. For spinal
administration, we externalized and fixed an end of the
catheter to the cranial side of the rat’s head. The dead vol-
ume of the catheters were 3.5 μL. Therefore, an artificial
cerebrospinal fluid (CSF) flush (10 μL) followed all i.t. in-
jections, in order to ensure complete delivery of recom-
binant human TGF-β1 (cat. 100-21; PeproTech, Rocky
Hill, NJ, USA) or vehicle. The composition of artificial
CSF was (in mM): 122.7 Cl−, 151.1 Na+, 2.6 K+, 1.3 Ca2+,
0.9 Mg2+, 21.0 HCO3
−, 2.5 HPO4
2−, and 3.5 dextrose, with
5 % CO2 in 95 % O2 to achieve a final pH of 7.3. Rats were
excluded from the study if they exhibited gross neuro-
logical injury or had fresh blood in the CSF 5 d after cath-
eter implantation. We also assessed locomotor functioning
using the Basso, Beattie, and Bresnahan (BBB) locomotor
scale [28], as described previously [13, 18].
Behavioral testing
We assessed thermal hyperalgesia according to the
method described by Hargreaves et al. [29] and our previ-
ous studies [30, 31]. In brief, rats were placed in
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platform, and hyperalgesia was assessed using an IITC
analgesiometer (IITC Inc., Woodland Hills, CA, USA).
We used a radiant heat source to target the middle of the
plantar surface with low-intensity heat (active intensity =
25) and a cut-off time of 30 s. Paw withdrawal latencies
(PWL) were recorded by observing behavioral indications
of nociception (withdrawal or licking). We transformed
PWL data into a percentage of the maximum possible ef-
fect (%MPE) using the following formula: % MPE = ((post-
drug latency − baseline)/(cut-off − baseline)) × 100 %. Post-
drug latency represents PWL measured after i.t. injection of
TGF-β1 or vehicle, and baseline represents PWL measured
immediately before i.t. injection.
Spinal immunohistofluorescence analyses
We mounted the rat lumbar spinal samples from multiple
groups into the same OCT block and simultaneously sec-
tioned them with a cryostat at −30 °C (HM550; Microm,
Waldorf, Germany) in order to decrease variation in the
immunohistochemical processes. Spinal immunohisto-
fluorescence analyses were conducted using a modifica-
tion of the method described by Sung et al. [32] and our
previous studies [18, 31]. For double immunofluorescence
staining of phosphorylated p38 (phospho-p38) and either
microglia or astrocyte markers, spinal sections (10 μm)
were incubated with a mixture of primary antibodies for
anti-phospho-p38 (1:100, Thr180/Tyr182, cat. 4511; Cell
Signaling Technology Inc., Beverly, MA, USA; monoclonal
rabbit antibody) and anti-OX-42 (CD11b, microglia
marker, 1:200, cat. CBL1512; EMD Millipore, Temecula,
CA, USA; monoclonal mouse antibody) or anti-glial fibril-
lary acidic protein (GFAP; astrocyte marker, 1:200, cat.
MAB3402; EMD Millipore; monoclonal mouse antibody)
antibodies, overnight at 4 °C. Spinal section were then in-
cubated with a mixture of Alexa Fluor 488-labeled chicken
anti-mouse IgG antibody (1:400, cat. A-21200; Molecular
Probes, Eugene, OR, USA; green fluorescence) and
DyLight 549-conjugated donkey anti-rabbit IgG antibody
(1:400, cat. 711-506-152; Jackson ImmunoResearch La-
boratories Inc., West Grove, PA, USA; red fluorescence)
for 40 min at room temperature. For double immuno-
fluorescence staining of phosphorylated ERK (phospho-
ERK) and microglia or astrocyte markers, spinal sections
(10 μm) were incubated with a mixture of primary anti-
bodies, anti-phospho-ERK antibodies (1:100, Thr202/
Tyr204, cat. 9101; Cell Signaling Technology Inc.; poly-
clonal rabbit antibody) and anti-OX-42 (1:200) or anti-
GFAP (1:200) antibodies, overnight at 4 °C. Spinal sections
were then incubated with a mixture of Alexa Fluor 488-
labeled chicken anti-mouse IgG antibody (1:400) and
DyLight 549-conjugated donkey anti-rabbit IgG antibody
(1:400) for 40 min at room temperature. We used a Leica
DM-6000 CS fluorescence microscope (Leica InstrumentsInc., Wetzlar, Germany) to visualize the stained spinal
sections, recorded images using a SPOT Xplorer Digital
camera (Diagnostic Instruments, Inc., Sterling Heights,
MI, USA), and then measured the pixel values of the
immunoreactive-positive areas using Image J software
(National Institutes of Health, Bethesda, MD, USA) with
three sections per rat. Spinal neurons distributed over the
superficial laminae (laminae I-III) respond to nociceptive
stimuli, and these neurons directly contribute to the trans-
mission of nociception [33]. Therefore, the superficial
laminae have more crucial roles in neuropathic pain com-
pared to the deep laminae. Thus, we quantified immuno-
reactivity for the targeted proteins in the superficial
laminae, as described by previous studies in rodents with
neuropathy [10, 33–35]. Immunofluorescence data is pre-
sented as a percentage change compared to the sham op-
eration plus vehicle group, which were regarded as 100 %.
Finally, for double immunofluorescence staining for neu-
rons and phospho-p38 or anti-phospho-ERK, spinal sec-
tions were incubated with a mixture of anti-neuronal
nuclei (NeuN; neuron-specific nuclear protein, 1:500,
Alexa Fluor 488 conjugated antibody, cat. MAB377X,
EMD Millipore, Temecula, CA, USA; monoclonal mouse
antibody) and anti-phospho-p38 (1:100) or anti-phospho-
ERK (1:100) antibodies overnight at 4 °C. Spinal sections
were then incubated with DyLight 549-conjugated
anti-rabbit IgG antibody (1:400) for 40 min at room
temperature.
Data and statistical analyses
All data are represented as means ± standard errors on the
mean (SEMs). Between groups differences were calculated
using one-way analyses of variance (ANOVAs). Effects
were further investigated using Student-Newman-Keuls
post hoc tests, with statistical significance set at P < 0.05.
Results
Effects of i.t. TGF-β1 on CCI-induced nociceptive behavior
Based on our previous findings [8], we selected a 5 ng
dose of TGF-β1 for the present study. At 14 d post-
surgery, i.t. injections of vehicle did not significantly
affect thermal hyperalgesia in rats with CCI (Fig. 1).
Compared to the vehicle group, the anti-hyperalgesic
effect of TGF-β1 reached the maximum %MPE at 0.5 h
after the i.t. injection, and then decreased gradually over
time. The effect persisted at > 50 % MPE for at least 6 h
after TGF-β1 administration. In addition, the vehicle-
and TGF-β1-treated CCI groups exhibited normal
behaviors (including locomotor function). We then fo-
cused on three time points (0.5, 3, and 6 h) after i.t. ad-
ministration of TGF-β1, in order to determine whether
modulation of spinal phospho-p38 and phospho-ERK
are involved in the antinociceptive effects of TGF-β1 in
neuropathic rats.
Time after i.t. injection (h)
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Fig. 1 Time course of anti-hyperalgesic effects of transforming
growth factor-β1 (TGF-β1) in rats with chronic constriction injury
(CCI) at 14 d post-surgery. The x-axis represents the time (h) from
intrathecal (i.t.) injection of vehicle or TGF-β1 (5 ng), and the y-axis
represents the percentage of the maximum possible effect (%MPE)
for anti-hyperalgesia. TGF-β1 significantly attenuated CCI-induced
thermal hyperalgesia in rats at 14 d post-surgery. Each point shows
the mean ± standard error of the mean (SEM) from six rats per




Fig. 2 The effects of intrathecal (i.t.) transforming growth factor-β1 (TGF-β1
phosphorylated (phospho)-p38 at 14 d post-surgery. Images represent cells
sham operated plus i.t. vehicle group (a), CCI plus i.t. vehicle group (b), and
TGF-β1 injections. Quantification of the phospho-p38 immunoreactivity (f)
upregulation of spinal phospho-p38. Each bar in (f) shows the mean ± stan
100 μm for all images (a–e). *P < 0.05 compared to the sham operated plu
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spinal phospho-p38 expression
Minimal and diffuse phospho-p38 immunoreactivity
occurred in the ipsilateral dorsal horn of the lumbar
spinal cord of the sham operated plus i.t. vehicle group
(Fig. 2a). Phospho-p38 immunoreactivity increased in
the ipsilateral spinal dorsal horn 14 d after CCI (Fig. 2b).
At 0.5 h after TGF-β1 treatment, there was no
significant inhibition of CCI-induced upregulation of
phospho-p38 immunoreactivity (Fig. 2c). Quantification
of the phospho-p38 immunoreactivity indicated that
TGF-β1 significantly reversed CCI-induced upregulation
of phospho-p38 immunoreactivity in the ipsilateral lum-
bar dorsal horn at 3 and 6 h after i.t. injections (Fig. 2f ).
We next examined the effects of i.t. injections of
TGF-β1 on the cellular specificity of phospho-p38
expression in neuropathic rats, using double immuno-
fluorescent staining. Neurons were labeled using anti-
NeuN antibody (a neuron-specific nuclear marker) [24].
Microglia were visualized with anti-OX-42 antibody,
which targets the microglial surface marker CD11b [24],
and astrocytes were identified with anti-GFAP antibody,
which labels the astrocytic intermediate filaments in the
cytoplasm [24]. In the sham operated plus i.t. vehicle
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) on chronic constriction injury (CCI)-induced upregulation of spinal
labeled with phospho-p38 (red) in the spinal cord, obtained from the
CCI plus i.t. TGF-β1 (5 ng) groups at 0.5 h (c), 3 h (d), and 6 h (e) after
demonstrates that TGF-β1 significantly inhibits CCI-induced
dard error of the mean (SEM) from six rats per group. Scale bars:
s vehicle group; #P < 0.05 compared to the CCI plus vehicle group
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was observed in neurons (Fig. 3b), microglia (Fig. 3e),
and astrocytes (Fig. 3h) at 14 d post-surgery in the CCI
plus vehicle group, which was attenuated by TGF-β1 3 h
after i.t. injections. In addition, CCI surgery activated
microglia at 14 d post-surgery, as indicated by upregu-
lation of OX-42 immunoreactivity and enlarged hyper-
trophic cell bodies with retraction of the cytoplasmic
processes (Fig. 3e) [36] Fig. 3e). Furthermore, we
observed activated astrocytes in rats with CCI at 14 d
post-surgery, as indicated by upregulation of GFAP im-
munoreactivity and hypertrophied cell bodies with
thickened processes (Fig. 3h) [37]. TGF-β1 markedly
attenuated these effects in microglia and astrocytes.
Effects of i.t. TGF-β1 on CCI-induced upregulation of
spinal phospho-ERK expression
In the sham operated plus i.t. vehicle group, there was
minimal and diffuse phospho-ERK immunoreactivity in
the ipsilateral dorsal horn of the lumbar spinal cord
(Fig. 4a). Phospho-ERK immunoreactivity significantly
increased in the ipsilateral spinal cord of rats with CCI
at 14 d post-surgery (Fig. 4b). At 0.5 h after i.t. injec-
tion, TGF-β1 treatment did not inhibit CCI-induced
upregulation of phospho-ERK immunoreactivity (Fig. 4c).Sham
phospho-p38      
+                         
NeuN
phospho-p38      
+                         
OX-42
phospho-p38      





Fig. 3 The effects of intrathecal (i.t.) transforming growth factor-β1 (TGF-β1
phosphorylated (phospho)-p38 in spinal neurons, microglia, and astrocytes
staining for phospho-p38 (red; a–i) with NeuN (neuronal-specific marker, gr
(astrocyte specific marker, green; g–i) in the lumbar spinal cord dorsal horn
group (b, e, and h), and CCI plus TGF-β1 group (c, f, and i) at 3 h after i.t. i
is localized to neurons, microglia, and astrocytes in the CCI plus vehicle gro
50 μm for all imagesQuantification of phospho-ERK immunoreactivity demon-
strated that i.t. TGF-β1 significantly inhibited CCI-
induced upregulation of phospho-ERK immunoreactivity
at 3 and 6 h after injection (Fig. 4f ). We next studied
the effects of i.t. TGF-β1 on the cellular specificity of
phospho-ERK expression in neuropathic rats using
double immunofluorescent staining. In the sham
operated plus i.t. vehicle group, phospho-ERK was not
localized to neurons (Fig. 5a), microglia (Fig. 5d), or
astrocytes (Fig. 5g). In contrast, at 14 d post-surgery,
upregulation of spinal phospho-ERK expression was
observed in microglia (Fig. 5e) and astrocytes (Fig. 5h)
of rats with CCI, which was markedly inhibited by
TGF-β1 at 3 h after i.t. injection. In addition, at 14 d
post-surgery, CCI resulted in both activated microglia
(Fig. 5e) and astrocytes (Fig. 5h); these effects were
also attenuated by i.t. TGF-β1.
Discussion
Summary of findings
In the present study, we found that i.t. TGF-β1 (5 ng)
attenuated CCI-induced thermal hyperesthesia for as long
as 6 h. Expression of phospho-p38 and phospho-ERK were
upregulated in the spinal dorsal horn following CCI, and i.t.
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at 14 d post-surgery. Merged images of double-immunofluorescence
een; a–c), OX-42 (microglial specific marker, green; d–f), and GFAP
of the sham operated plus vehicle group (a, d, and g), CCI plus vehicle
njections. The results demonstrate that spinal phospho-p38 expression
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Fig. 4 Effects of intrathecal (i.t.) transforming growth factor-β1 (TGF-β1) on chronic constriction injury (CCI)-induced upregulation of spinal
phosphorylated extracellular signal-regulated kinase (phospho-ERK) at 14 d post-surgery. Images represent cells labeled with phospho-ERK (red) in
the spinal cord, obtained from the sham operated plus i.t. vehicle group (a), CCI plus i.t. vehicle group (b), and CCI plus i.t. TGF-β1 (5 ng) groups
at 0.5 h (c), 3 h (d), and 6 h (e) after TGF-β1 injections. Quantification of phospho-ERK immunoreactivity (f) demonstrates that TGF-β1 significantly
inhibits CCI-induced upregulation of spinal phospho-ERK. Each bar in (f) shows the mean ± standard error of the mean (SEM) from six rats per
group. Scale bars: 100 μm for all images (a–e). *P < 0.05 compared to the sham operated plus vehicle group; #P < 0.05 compared to the CCI plus
vehicle group
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and astrocytes in the spinal dorsal horn following CCI.
However, expression of phospho-p38 and phospho-ERK
are more prominent in astrocytes. In addition, p38 occurs
to a greater extent than ERK upregulation in neurons after
CCI, and the expression of phospho-p38 in neurons is also
downregulated after i.t. TGF-β1.
The roles of spinal p38 and ERK in neuropathy
Clinical neuropathic pain syndromes are characterized by
evoked pain, including hyperalgesia [38], which is repre-
sented as thermal hyperalgesia in the rat CCI model.
Central sensitization in the spinal dorsal horn contributes
to the hypersensitive pain behaviors associated with neur-
opathy [39]. Activation of microglia and astrocytes
contribute to spinal neuroinflammation [40, 41] and accel-
erate central sensitization, as well as development and
maintenance of neuropathic pain [11, 12]. Activated
microglia and astrocytes in the spinal dorsal horn indicate
elevated nociceptive states [18–20, 42–47], and CCI also
resulted in activated microglia and astrocytes in the spinal
cord at 14 d post-surgery. Phosphorylation of Tyr-182 and
Thr-180 result in p38 activation [48]. Spinal phospho-p38expression was only observed in neurons in the sham op-
erated plus i.t. vehicle group. At 14 d post-surgery, upreg-
ulation of spinal phospho-p38 expression was observed in
neurons, microglia, and astrocytes in rats with CCI. Moon
et al. found that phospho-p38 staining was localized to
neurons and astrocytes in the spinal cord of mice with
CCI [49], and Gu et al. reported phospho-p38 in spinal
microglia of rats with CCI [50]. The activated form of
ERK is phosphorylated on both Thr-202 and Tyr-204 [51].
In the sham operated group, spinal phospho-ERK was not
localized to neurons, microglia, or astrocytes. Upregula-
tion of spinal phospho-ERK expression was observed in
microglia and astrocytes of CCI rats, but not in neurons.
However, the possibility that spinal neurons may also be a
source of phospho-ERK expression cannot be excluded.
Our double-immunostaining images further confirmed
that spinal astrocytes are a major source of phospho-p38
and phospho-ERK upregulation in rats with CCI, com-
pared to microglia. Our findings are consistent with a
previous report that phospho-ERK is predominantly lo-
calized to astrocytes and minimally localized to micro-
glia, but not localized to neurons in the spinal cord 21
d after spinal nerve ligation [24]. Our findings also
CCI + TGF- 1 CCISham
phospho-ERK
+                         
NeuN
phospho-ERK
+                         
OX-42
phospho-ERK





Fig. 5 Effects of intrathecal (i.t.) transforming growth factor-β1 (TGF-β1) on chronic constriction injury (CCI)-induced upregulation of
phosphorylated extracellular signal-regulated kinase (phospho-ERK) in spinal neurons, microglia, and astrocytes at 14 d post-surgery.
Merged images of double-immunofluorescence staining for phospho-ERK (red; a–i) with NeuN (neuronal-specific marker, green; a–c),
OX-42 (microglial specific marker, green; d–f), and GFAP (astrocyte specific marker, green; g–i) in the lumbar spinal cord dorsal horn,
obtained from the sham operated plus vehicle group (a, d, and g), CCI plus vehicle group (b, e, and h), and CCI plus TGF-β1 group
(c, f, and i) at 3 h after i.t. injections. The results demonstrate that spinal phospho-ERK expression is primarily localized to microglia
and astrocytes in the CCI plus vehicle group (yellow; white arrow), and is attenuated by i.t. TGF-β1. Scale bars: 50 μm for all images
Chen et al. The Journal of Headache and Pain  (2016) 17:72 Page 7 of 9support the hypothesis that spinal astrocytes contribute
to maintaining neuropathic pain [13, 14, 24, 52].
Contributions of p38 and ERK to the antinociceptive
effects of TGF-β1
CCI evokes significant downregulation of spinal TGF-
β1 protein in rats [8, 10, 53]. Similarly to previous
results [8], we found that i.t. TGF-β1 attenuated CCI-
induced thermal hyperesthesia in rats. Le et al. re-
ported that TGF-β1 inhibits lipopolysaccharide (LPS)-
induced phosphorylation of both p38 and ERK in a
murine microglial cell line [54]. Similarly to this previ-
ous study, we found that TGF-β1 administration to
rats reduced peripheral CCI-induced upregulation of
phospho-p38 and phospho-ERK in activated spinal
microglia. We also discovered that TGF-β1 reduced
peripheral CCI-induced upregulation of phospho-p38
and phospho-ERK in activated rat spinal astrocytes.
I.t. administration of a p38 inhibitor (SB203580) re-
duces neuropathic pain in animal models [22, 23, 25],
and spinal nerve ligation-induced mechanical allody-
nia is attenuated by i.t. administration of the MAPK
and ERK kinase (MEK; ERK kinase) inhibitor PD98059
[24]. At 0.5 h after i.t. injections, TGF-β1 did not inhibit
CCI-induced upregulation of phospho-p38 or phospho-ERK immunoreactivity. However, the anti-hyperalgesic ef-
fects of TGF-β1 in rats with CCI reached the maximum
%MPE at 0.5 h after administration. At 3 and 6 h after ad-
ministration, TGF-β1 significantly suppressed CCI-
induced upregulation of phospho-p38 and phospho-ERK
immunoreactivity for the duration of time that the anti-
hyperalgesic effects of TGF-β1 remained at > 50 % MPE.
We previously reported that i.t. TGF-β1 (5 ng) reduced
CCI-induced upregulation of spinal TNF-α [8] for the
same duration of time that TGF-β1 inhibited CCI-induced
phospho-p38 and phospho-ERK upregulation in the
present study. These results are consistent with the find-
ing that inhibiting activation of p38 and ERK block TNF-α
gene expression in endotoxin-activated primary microglia
and astrocytes [15]. Therefore, we suggest that inhibition
of spinal phospho-p38 and phospho-ERK are primarily
associated with the maintenance phase, but not with
the development phase, of the antinociceptive effects of
TGF-β1 during neuropathic pain.
Conclusions
Based on the present results and the findings of previous
studies, we hypothesize that the antinociceptive effects of
TGF-β1 are mediated by two different mechanisms (Fig. 6).












phospho-p38 ,    
phospho-ERK 
Fig. 6 Schematic representation of possible mechanisms for the
antinociceptive effects of intrathecal (i.t.) transforming growth factor-β1
(TGF-β1) during neuropathic pain. I.t. TGF-β1 may attenuate peripheral
nerve injury-induced thermal hyperalgesia (Pathway 1). Upregulation of
phosphorylated (phospho)-p38 and phosphorylated extracellular signal-
regulated kinase (phospho-ERK) is a mechanism for nerve injury-induced
pain (Pathway 2). The antinociceptive effects of i.t. TGF-β1 may occur via
suppression of nerve injury-induced upregulation of phospho-p38 and
phospho-ERK (Pathway 3)
Chen et al. The Journal of Headache and Pain  (2016) 17:72 Page 8 of 9demonstrated by the present study and our previous study
[8]. Second, nerve injury may upregulate expression of
phospho-p38 and phospho-ERK in spinal microglia and
astrocytes, which may induce neuropathic pain behaviors.
TGF-β1 may directly inhibit expression of phospho-p38
and phospho-ERK in microglia and astrocytes, which may
reduce neuroinflammation, thereby attenuating neuro-
pathic pain behavior in rats. Therefore, TGF-β1 is a prom-
ising therapeutic strategy for neuropathic pain.
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